MA34979B1 - Molecules de liaisonbispecifiques se liant a vegf et ang2 - Google Patents

Molecules de liaisonbispecifiques se liant a vegf et ang2

Info

Publication number
MA34979B1
MA34979B1 MA36274A MA36274A MA34979B1 MA 34979 B1 MA34979 B1 MA 34979B1 MA 36274 A MA36274 A MA 36274A MA 36274 A MA36274 A MA 36274A MA 34979 B1 MA34979 B1 MA 34979B1
Authority
MA
Morocco
Prior art keywords
vegf
ang2
binding molecules
binding
bispecific binding
Prior art date
Application number
MA36274A
Other languages
English (en)
Inventor
Andreas Gschwind
Rene Georg Ott
Joachim Boucneau
Marie-Ange Buyse
Erik Depla
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45895502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34979(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34979B1 publication Critical patent/MA34979B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des molécules de liaison bispécifiques se liant à la fois à VEGF et à Ang2, de préférence sous la forme de domaines variables uniques d'immunoglobuline, tels que des VHH et des anticorps à domaine, des compositions pharmaceutiques contenant celles-ci et leur utilisation dans le traitement de maladies qui sont associées à des effets à médiation par VEGF et/ou Ang2 sur l'angiogenèse. L'invention concerne en outre des acides nucléiques codant pour des molécules de liaison bispécifiques, des cellules hôtes et des procédés de préparation associés.
MA36274A 2011-04-01 2012-03-30 Molecules de liaisonbispecifiques se liant a vegf et ang2 MA34979B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11160921 2011-04-01
PCT/EP2012/055901 WO2012131078A1 (fr) 2011-04-01 2012-03-30 Molécules de liaison bispécifiques se liant à vegf et à ang2

Publications (1)

Publication Number Publication Date
MA34979B1 true MA34979B1 (fr) 2014-03-01

Family

ID=45895502

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36274A MA34979B1 (fr) 2011-04-01 2012-03-30 Molecules de liaisonbispecifiques se liant a vegf et ang2

Country Status (36)

Country Link
US (4) US9527925B2 (fr)
EP (2) EP3144322A3 (fr)
JP (2) JP6023786B2 (fr)
KR (1) KR101907572B1 (fr)
CN (2) CN105820243A (fr)
AP (1) AP2013007085A0 (fr)
AR (1) AR085984A1 (fr)
AU (2) AU2012237234B2 (fr)
BR (1) BR112013025304B1 (fr)
CA (1) CA2827817C (fr)
CL (1) CL2013002623A1 (fr)
CO (1) CO6801639A2 (fr)
CY (1) CY1118339T1 (fr)
DK (1) DK2694546T3 (fr)
EA (2) EA025148B1 (fr)
EC (1) ECSP13013001A (fr)
ES (1) ES2606302T3 (fr)
HK (1) HK1225400A1 (fr)
HR (1) HRP20161689T1 (fr)
HU (1) HUE030148T2 (fr)
IL (1) IL227936B (fr)
LT (1) LT2694546T (fr)
MA (1) MA34979B1 (fr)
MX (2) MX343440B (fr)
MY (1) MY171007A (fr)
PE (1) PE20140448A1 (fr)
PH (1) PH12013502044A1 (fr)
PL (1) PL2694546T3 (fr)
PT (1) PT2694546T (fr)
RS (1) RS55361B1 (fr)
SG (2) SG10201602373TA (fr)
SI (1) SI2694546T1 (fr)
TN (1) TN2013000390A1 (fr)
UA (1) UA114707C2 (fr)
UY (1) UY33998A (fr)
WO (1) WO2012131078A1 (fr)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US9527925B2 (en) * 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
CA2865464C (fr) * 2012-03-30 2022-07-12 Boehringer Ingelheim International Gmbh Molecules de liaison a ang2
LT3495387T (lt) 2012-07-13 2021-11-25 Roche Glycart Ag Bispecifiniai anti-vegf / anti-ang-2 antikūnai ir jų panaudojimas akių kraujagyslių ligoms gydyti
CA2883880A1 (fr) * 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Combinaisons pharmaceutiques comprenant des liants doubles angiopoietine-2/dll4 et des agents anti-vegf
BR112015006363A2 (pt) * 2012-09-28 2017-08-08 Boehringer Ingelheim Int combinações farmacêuticas compreendendo ligantes angiopoietina-2/dll4 duplos e agentes anti-vegf-r
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
CN107106683B (zh) * 2015-01-16 2021-07-20 中央研究院 含靶向与效应组件的分子构建体
AR103477A1 (es) * 2015-01-28 2017-05-10 Lilly Co Eli Compuestos de vegfa / ang2
KR102789821B1 (ko) 2015-03-31 2025-04-02 소리소 파마슈티컬스 인크. 프로테아제-절단가능 링커를 갖는 펩티드 구조물
MX2017012662A (es) 2015-03-31 2018-05-11 Vhsquared Ltd Polipeptidos.
JP2018511346A (ja) 2015-03-31 2018-04-26 ブイエイチスクエアード リミテッド ポリペプチド
HUE051165T2 (hu) * 2015-07-29 2021-03-01 Allergan Inc ANG-2 elleni, csak nehézláncot tartalmazó antitestek
CA2992788A1 (fr) 2015-08-14 2017-02-23 Allergan, Inc. Anticorps a chaine lourde uniquement contre le pgdf
JP6959912B2 (ja) * 2015-09-23 2021-11-05 ジェネンテック， インコーポレイテッド 抗ｖｅｇｆ抗体の最適化変異体
ES2905912T3 (es) * 2015-11-13 2022-04-12 Ablynx Nv Dominios variables de inmunoglobulina de unión a albúmina sérica mejorados
KR102802241B1 (ko) 2015-12-04 2025-05-07 베링거 인겔하임 인터내셔날 게엠베하 종양 세포에서 wnt 신호 전달을 길항하는 바이파라토픽 폴리펩타이드
JP6949106B2 (ja) 2016-08-23 2021-10-13 メディミューン リミテッド 抗ｖｅｇｆ−ａ抗体ならびにそれらの使用
EP3504237A1 (fr) * 2016-08-23 2019-07-03 Medimmune Limited Anticorps anti-vegf-a et anti-ang2 et leurs utilisations
CN110072519A (zh) * 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
RU2648164C1 (ru) * 2016-12-19 2018-03-22 Федеральное государственное учреждение науки Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Селективный бифункциональный препарат на основе фрагментов одноцепочечных антител верблюжьих, нацеленный на опухолевые рецепторы cd47/erbb2, предназначенный для терапии злокачественных новообразований
WO2018114728A1 (fr) 2016-12-20 2018-06-28 F. Hoffmann-La Roche Ag Polythérapie par anticorps bispécifique anti-ang2/vegf et anticorps bispécifique anti-her2
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
TWI887192B (zh) 2017-05-31 2025-06-21 比利時商艾伯林克斯公司 拮抗腫瘤細胞中wnt訊息傳導之多肽
CA3061053A1 (fr) * 2017-06-02 2018-12-06 Boehringer Ingelheim International Gmbh Polytherapie anticancereuse
WO2019154776A1 (fr) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Traitement de maladies ophthalmologiques
US12171764B2 (en) * 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2020006516A1 (fr) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antagonistes des régulateurs de points de contrôle immunitaires antitumoraux
SG11202103064YA (en) 2018-10-29 2021-05-28 Hoffmann La Roche Antibody formulation
US20220185875A1 (en) * 2019-03-18 2022-06-16 Jiangsu Hengrui Medicine Co., Ltd. Bispecific antibody specifically bound to vegf and ang2
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
CN114514243B (zh) 2019-06-21 2025-01-24 索瑞索制药公司 多肽
EP3986571A1 (fr) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Polypeptides
EP3986570A1 (fr) 2019-06-21 2022-04-27 Sorriso Pharmaceuticals, Inc. Compositions
EP3990116A1 (fr) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFß1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
CN110452297B (zh) * 2019-09-03 2020-04-14 上海洛启生物医药技术有限公司 抗vegf单域抗体及其应用
JP7734132B2 (ja) * 2019-12-11 2025-09-04 カリナン セラピューティクス インコーポレイテッド 抗血清アルブミン抗体
EP4073122A4 (fr) 2019-12-11 2024-03-27 Cullinan Oncology, Inc. Anticorps anti-cd19 et protéines de liaison multi-spécifiques
WO2021155151A1 (fr) * 2020-01-29 2021-08-05 The Methodist Hospital System Ligands multivalents ciblant des récepteurs de surface cellulaire et plateforme de mesure de force pour leur fabrication
WO2021209458A1 (fr) 2020-04-14 2021-10-21 Ares Trading S.A. Traitement combiné du cancer
JP7560185B2 (ja) 2020-07-07 2024-10-02 カナプ セラピューティクス インコーポレイテッド 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用
EP4237423B1 (fr) 2020-11-02 2024-12-11 Boehringer Ingelheim International GmbH 1h-pyrazolo[4,3-c]pyridines substitués et dérivés en tant qu'inhibiteurs de l'egfr
EP4019548A1 (fr) * 2020-12-23 2022-06-29 Vrije Universiteit Brussel Vhh anti lag3 et leurs utilisations
US20240287168A1 (en) * 2021-02-10 2024-08-29 Shanghai Jemincare Pharmaceutical Co., Ltd. Anti-vegf antibody and use thereof
CA3208389A1 (fr) * 2021-02-19 2022-08-25 Ignacio ASIAL Molecules de liaison a vegfa
WO2022231930A1 (fr) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
WO2022256820A1 (fr) 2021-06-03 2022-12-08 Gensun Biopharma Inc. Antagonistes multispécifiques
CN117500828A (zh) * 2021-06-04 2024-02-02 信达生物制药(苏州)有限公司 结合VEGF和Ang2的双特异性结合分子以及其用途
EP4386004A4 (fr) * 2021-08-13 2025-08-13 Innovent Biologics Suzhou Co Ltd Anticorps bispécifique anti-vegf a et anti-vegf c et son utilisation
MX2024002962A (es) * 2021-09-10 2024-05-17 Soter Biopharma Pte Ltd Anticuerpo anti-ang2, metodo de preparacion del mismo y aplicacion del mismo.
CU24770B1 (es) * 2021-12-15 2025-09-01 Ct Ingenieria Genetica Biotecnologia Polipéptidos que se unen al factor de crecimiento del endotelio vascular y al factor básico de crecimiento de fibroblastos
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
JP2025534252A (ja) * 2022-09-14 2025-10-15 尋済生物科技（北京）有限公司 抗ｖｅｇｆａ抗体またはその抗原結合フラグメント、およびその使用
WO2024055995A1 (fr) 2022-09-14 2024-03-21 寻济生物科技（北京）有限公司 Protéine de fusion anti-vegfa, son procédé de préparation et son utilisation
EP4596579A1 (fr) * 2022-09-28 2025-08-06 Kexing Biopharm Co., Ltd. Anticorps ou fragment de liaison à l'antigène capable d'identifier ang-2, et anticorps bispécifique pour identifier simultanément vegf et ang-2
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
AR131237A1 (es) * 2022-12-01 2025-02-26 Innovent Biologics Suzhou Co Ltd Formulación que comprende una molécula de unión biespecífica que se une a vegf y a ang2 y uso de la misma
KR20250139273A (ko) * 2022-12-01 2025-09-23 이노벤트 바이오로직스 (쑤저우) 컴퍼니, 리미티드 삼중특이적 융합 단백질 및 이의 용도
WO2024178730A1 (fr) * 2023-03-02 2024-09-06 清华大学 Médicament protéique cristallisable anti-vegf intravitréen pour inhiber la néovascularisation choroïdienne
WO2025111816A1 (fr) * 2023-11-28 2025-06-05 Eluminex Biosciences Limited Protéines de fusion multispécifiques ciblant des facteurs angiogéniques, inflammatoires et/ou fibrotiques
WO2025189977A1 (fr) * 2024-03-13 2025-09-18 寻济生物科技（北京）有限公司 Construction de fusion anti-vegfa, son procédé de préparation et son utilisation
WO2025219504A1 (fr) 2024-04-19 2025-10-23 F. Hoffmann-La Roche Ag Traitement de maladies ophtalmologiques
CN121517578A (zh) * 2024-08-13 2026-02-13 长春金赛药业有限责任公司 同时结合VEGF及Ang-2的Fc融合蛋白及其用途
CN121405805B (zh) * 2025-09-25 2026-04-28 首都医科大学附属北京朝阳医院 一种抗人源整合素cd103纳米抗体与应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1621554E (pt) 1992-08-21 2009-07-13 Univ Bruxelles Imunoglobtainas desprovidas de cadeias leves
US5408535A (en) 1993-09-07 1995-04-18 Miles Inc. Video test strip reader and method for evaluating test strips
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
EP0739981A1 (fr) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Fragments variables d'immunoglobulines-utilisation thérapeutique ou vétérinaire
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
IL132240A0 (en) 1997-04-07 2001-03-19 Genentech Inc Anti-vegf antibodies
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
EP1274720A4 (fr) 2000-04-12 2004-08-18 Human Genome Sciences Inc Proteines fusionnees a l'albumine
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
EP1463752A4 (fr) 2001-12-21 2005-07-13 Human Genome Sciences Inc Proteines de fusion d'albumine
AU2003217912A1 (en) * 2002-03-01 2003-09-16 Xencor Antibody optimization
WO2003074670A2 (fr) 2002-03-01 2003-09-12 Ball Horticultural Company Promoteur lis pour l'expression de transgenes dans des tissus floraux
CA2497226A1 (fr) 2002-09-10 2004-03-25 Lorantis Limited Compositions pharmaceutiques et traitements medicaux comprenant des proteines a ligand notch
EP2284192A3 (fr) 2002-11-08 2011-07-20 Ablynx N.V. Anticorps de Camelidae pour administration sublinguale
US20050043220A1 (en) 2002-11-08 2005-02-24 Guyer David R. Methods and compositions for treating macular degeneration
EP1558647B1 (fr) 2002-11-08 2015-06-10 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
JP4490290B2 (ja) 2002-12-31 2010-06-23 ネクター セラピューティクス アラバマ，コーポレイション 加水分解安定性マレイミド末端ポリマー
SI1639011T1 (sl) 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
NZ592039A (en) 2003-08-27 2013-03-28 Ophthotech Corp Combination therapy for the treatment of ocular neovascular disorders
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
US20050284249A1 (en) 2004-06-29 2005-12-29 Arnone David F Worm type gear mover assembly
WO2006040153A2 (fr) 2004-10-13 2006-04-20 Ablynx N.V. Nanocorps™ contre la proteine beta-amyloide et polypeptides les renfermant pour le traitement de maladies degeneratives neurales, telles que la maladie d'alzheimer
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
SV2006002342A (es) 2004-12-17 2006-06-01 Genentech Inc Terapia de antiogenesis para enfermedades autoinmunes en pacientes que tuvieron la terapia anterior interrumpida
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
AU2006249144B2 (en) * 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2007014564A (es) 2005-05-20 2008-02-07 Ablynx Nv Anticuerpos de vhh de dominio unico contra el factor de von willebrand.
WO2007053186A2 (fr) 2005-05-31 2007-05-10 Labnow, Inc. Méthodes et compositions en rapport avec la détermination et l’utilisation de la numération de globules blancs
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007028110A2 (fr) 2005-09-01 2007-03-08 Vasgene Therapeutics, Inc. Methodes d'utilisation et d'identification de modulateurs de delta-like 4
WO2007043109A1 (fr) 2005-09-30 2007-04-19 Fujitsu Limited Stockage d’informations
EP2518083A3 (fr) * 2005-12-15 2012-12-05 Medimmune Limited Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du VEGF-A et/ou du KDR et/ou du FLTL pour le traitement du cancer
DK1962895T3 (da) 2005-12-16 2013-03-04 Regeneron Pharma TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST
TW200804593A (en) 2006-01-24 2008-01-16 Domantis Ltd Fusion proteins that contain natural junctions
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US7570881B2 (en) 2006-02-21 2009-08-04 Nokia Corporation Color balanced camera with a flash light unit
US20070269422A1 (en) * 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
WO2007143689A2 (fr) 2006-06-06 2007-12-13 Genentech, Inc. Compositions et procédés destinés à moduler le développement vasculaire
AR061246A1 (es) 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
UA95304C2 (ru) 2006-08-07 2011-07-25 Ридженерон Фармасьютикалз, Инк. Применение антагониста dll4 для предотвращения или снижения потери кровеносных сосудов
CA2666599A1 (fr) 2006-08-18 2008-02-21 Ablynx N.V. Sequences d'acides amines dirigees contre l'il-6r et polypeptides les contenant utilises pour le traitement de maladies et de troubles associes au signal medie par il-6
CN101646689A (zh) * 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
JP2010505435A (ja) 2006-10-11 2010-02-25 アブリンクス エン．ヴェー． 本質的にｐＨに非依存的に血清タンパク質に結合するアミノ酸配列、それを含む化合物、およびその使用
CA2666974A1 (fr) 2006-10-20 2008-11-06 Schering Corporation Anticorps anti-vegf entierement humains et leurs procedes d'utilisation
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
CN101663319A (zh) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 针对血管内皮生长因子的氨基酸序列和包括其的多肽用于治疗特征在于过量和/或病理性血管发生或新血管形成的病症和疾病
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
CN104497143B (zh) * 2007-03-29 2020-08-25 健玛保 双特异性抗体及其制造方法
GB0709333D0 (en) 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
NZ580530A (en) 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
EP2014680A1 (fr) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne
US8216571B2 (en) 2007-10-22 2012-07-10 Schering Corporation Fully human anti-VEGF antibodies and methods of using
HUE027358T2 (en) 2007-11-26 2016-09-28 Bayer Ip Gmbh Anti-mesothelin antibodies and their applications
WO2009095489A2 (fr) 2008-02-01 2009-08-06 Ablynx N.V. Séquences d'acides aminés améliorées dirigées contre il-6r et polypeptides les comprenant pour le traitement de maladies et troubles associés à une signalisation facilitée par il-6
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2717015A1 (fr) 2008-03-05 2009-09-11 Ablynx Nv Nouveaux complexes dimeres de fixation a des antigenes, procedes de fabrication et utilisations associes
NZ587706A (en) 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
AU2009235467A1 (en) 2008-04-07 2009-10-15 Ablynx Nv Single variable domains against the Notch pathways
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
HUE042053T2 (hu) 2008-06-05 2019-06-28 Ablynx Nv Vírus burokfehérjéi elleni aminosav-szekvenciák és az azokat tartalmazó polipeptidek virális betegségek kezelésére
HRP20241467T1 (hr) 2008-06-25 2025-01-03 Novartis Ag Stabilna i topljiva protutijela koja inhibiraju vegf
RU2547596C2 (ru) 2008-09-03 2015-04-10 Дженентек, Инк. Полиспецифические антитела
CN102264763B (zh) 2008-09-19 2016-04-27 米迪缪尼有限公司 定向于dll4的抗体及其用途
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
EP2364328A2 (fr) 2008-12-10 2011-09-14 Ablynx NV Séquences d'acides aminés dirigés contre le système angiopoïétine/tie et polypeptides les incluant dans le traitement de pathologies et de troubles apparentés à l'angiogenèse
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CN104374932A (zh) 2009-01-13 2015-02-25 Fio公司 与电子设备和快速诊断测试中的测试盒结合使用的手持诊断测试设备
WO2010124009A2 (fr) 2009-04-21 2010-10-28 Schering Corporation Anticorps anti-vegf entièrement humains et méthodes d'utilisation de ceux-ci
AU2010245011B2 (en) 2009-04-27 2015-09-03 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
BRPI1012321A8 (pt) 2009-06-17 2016-09-27 Abbott Biotherapeutics Corp Anticorpos anti-vegf e seus usos
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
UY32920A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moleculas de unión biespecíficas para la terapia anti-angiogénesis
US20110195494A1 (en) 2009-10-02 2011-08-11 Boehringer Ingelheim International Gmbh Dll4-binging molecules
TWI619509B (zh) 2010-02-23 2018-04-01 建南德克公司 治療先前未經治療之ⅲ期或ⅳ期卵巢癌、輸卵管癌或原發性腹膜癌之卡鉑、太平洋紫杉醇與抗-vegf抗體之組合
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012012499A1 (fr) 2010-07-20 2012-01-26 Nurx Pharmaceuticals, Inc. Système de lecteur optique
US20120225081A1 (en) * 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
JP2014500712A (ja) 2010-11-02 2014-01-16 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US20130078247A1 (en) * 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
KR20140043351A (ko) 2011-05-27 2014-04-09 노파르티스 아게 시력 장애의 치료 방법
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
CA2865464C (fr) * 2012-03-30 2022-07-12 Boehringer Ingelheim International Gmbh Molecules de liaison a ang2
US9292583B2 (en) * 2012-11-27 2016-03-22 Google Inc. Method of displaying search results

Also Published As

Publication number Publication date
US20170247475A1 (en) 2017-08-31
AU2017200237A1 (en) 2017-02-02
BR112013025304A2 (pt) 2017-06-06
MY171007A (en) 2019-09-23
HRP20161689T1 (hr) 2017-02-24
SG193561A1 (en) 2013-11-29
AU2012237234A1 (en) 2013-09-05
EP3144322A2 (fr) 2017-03-22
EP2694546B1 (fr) 2016-09-21
UY33998A (es) 2012-09-28
ECSP13013001A (es) 2013-12-31
MX2013010949A (es) 2014-06-06
PL2694546T3 (pl) 2017-03-31
IL227936B (en) 2018-06-28
RS55361B1 (sr) 2017-03-31
US20220017642A1 (en) 2022-01-20
AP2013007085A0 (en) 2013-08-31
CA2827817C (fr) 2020-12-15
UA114707C2 (uk) 2017-07-25
CA2827817A1 (fr) 2012-10-04
KR20140018317A (ko) 2014-02-12
PT2694546T (pt) 2016-12-28
JP6023786B2 (ja) 2016-11-09
CY1118339T1 (el) 2017-06-28
BR112013025304B1 (pt) 2022-10-11
CN103562222B (zh) 2016-04-06
TN2013000390A1 (en) 2015-01-20
US9527925B2 (en) 2016-12-27
ES2606302T3 (es) 2017-03-23
PE20140448A1 (es) 2014-04-13
US20130078248A1 (en) 2013-03-28
KR101907572B1 (ko) 2018-10-15
AU2017200237B2 (en) 2018-05-17
HUE030148T2 (en) 2017-04-28
JP6297657B2 (ja) 2018-03-20
US20200010569A1 (en) 2020-01-09
CO6801639A2 (es) 2013-11-29
CL2013002623A1 (es) 2014-02-14
WO2012131078A1 (fr) 2012-10-04
CN105820243A (zh) 2016-08-03
LT2694546T (lt) 2016-11-10
DK2694546T3 (en) 2016-12-05
EA201600338A1 (ru) 2016-09-30
CN103562222A (zh) 2014-02-05
MX337543B (es) 2016-03-10
NZ614249A (en) 2015-05-29
SG10201602373TA (en) 2016-05-30
EA025148B1 (ru) 2016-11-30
AU2012237234B2 (en) 2016-10-20
EA036746B1 (ru) 2020-12-16
EP2694546A1 (fr) 2014-02-12
JP2014515602A (ja) 2014-07-03
SI2694546T1 (sl) 2017-01-31
EA201301108A1 (ru) 2014-03-31
PH12013502044A1 (en) 2013-12-16
HK1225400A1 (zh) 2017-09-08
IL227936A0 (en) 2013-09-30
MX343440B (es) 2016-11-07
JP2017023152A (ja) 2017-02-02
EP3144322A3 (fr) 2017-05-31
HK1190412A1 (zh) 2014-07-04
US10414828B2 (en) 2019-09-17
US11161916B2 (en) 2021-11-02
AR085984A1 (es) 2013-11-13

Similar Documents

Publication Publication Date Title
MA35233B1 (fr) Molecules de liaison bispecifiques se liant à dii4 et ang2
MA33609B1 (fr) Molecules de liaison a dll4
MA33607B1 (fr) Molécules de liaison bispécifiques pour une thérapie anti-angiogénique
Couturier et al. Activation of phagocytic activity in astrocytes by reduced expression of the inflammasome component ASC and its implication in a mouse model of Alzheimer disease
Li et al. Lipopolysaccharide differentially affects the osteogenic differentiation of periodontal ligament stem cells and bone marrow mesenchymal stem cells through Toll-like receptor 4 mediated nuclear factor κB pathway
Komai et al. Role of scavenger receptors as damage-associated molecular pattern receptors in Toll-like receptor activation
MA32928B1 (fr) Anticorps anti-cxcr4 et leur utilisation pour le traitement du cancer
EA201301108A1 (ru) Биспецифические связывающие молекулы, связывающиеся с vegf и ang2
EA201100239A1 (ru) Композиции, одновалетные в отношении связывания cd28, и способы их применения
MA34175B1 (fr) Anticorps anti-cxcr4 humanisés pour le traitement de cancer
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
MA56289B1 (fr) Mutéines d'interleukine-21 et méthodes de traitement
MA44547A1 (fr) Anticorps anti-pd-1,procédé de leur production et de leur utilisation
MA35659B1 (fr) Protéine de liaison à un antigène et son utilisation comme produit d'adressage pour le traitement du cancer
MA67580B1 (fr) Oligonucléotides pour induire l'expression de paternal ube3a
UA116194C2 (uk) Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном
MA33285B1 (fr) Anticorps anti-cxcr4 pour le traitement du vih
MA37794B1 (fr) Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
MA34721B1 (fr) Acides carboxyliques 1-benzylcycloalkyle substitués et leur utilisation
EA200970250A1 (ru) Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MA41596B1 (fr) Anticorps anti-tau et leurs utilisations
EA200900424A1 (ru) Человеческие антитела, которые связываются с cxcr4, и их применение
MA38190A2 (fr) Inhibiteurs d'autotaxine
JOP20220357A1 (ar) ربط أجسام مضادة متعددة الخصوصية مع bcma